Supernus and Indivior Agree to $2.2 Billion Revenue Merger to Create CNS Biopharma Leader

Supernus Pharmaceuticals Inc. (Nasdaq: SUPN) and Indivior Pharmaceuticals Inc. (Nasdaq: INDV) have agreed to merge in an all-stock transaction that... Read More

The post Supernus and Indivior Agree to $2.2 Billion Revenue Merger to Create CNS Biopharma Leader appeared first on citybiz.